Progesterone exposure and breast cancer risk: Understanding the biological roots

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 283-286

  Joshi, Purna A ^a   Goodwin, Pamela J ^b   Khokha, Rama ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADVERSE EFFECTS; BREAST TUMOR; CHEMICALLY INDUCED; ESTROGEN THERAPY; FEMALE; HUMAN;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE;

EID: 84994496802     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0512     Document Type: Editorial

References (11)

1. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative randomized clinical trials [published online April 16, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.0494.
2. Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod. 2001;65(3):680-688.
3. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803-807.
4. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol. 2002;15(12):1348-1356.
5. Chlebowski RT, Anderson G, Pettinger M, et al; Women's Health Initiative Investigators. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168(4):370-377.
6. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98-102.
7. Lim E, Vaillant F, Wu D, et al; kConFab. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907-913.
8. Shehata M, Teschendorff A, Sharp G, et al. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res. 2012;14(5):R134.
9. Joshi PA, Di Grappa MA, Khokha R. Active allies: hormones, stem cells and the niche in adult mammopoiesis. Trends Endocrinol Metab. 2012;23(6):299-309.
10. Jackson HW, Waterhouse P, Sinha A, Kislinger T, Berman HK, Khokha R. Expansion of stem cells counteracts age-related mammary regression in compound Timp1/Timp3 null mice. Nat Cell Biol. 2015;17(3):217-227.
11. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78-81.